During Wednesday’s current trade, Dover Corp (NYSE:DOV)’s shares incline 1.17% to $72.75.
Dover Corporation (DOV) The Company is predictable to benefit from its acquisition strategy, supply chain rationalization, improved capital allocation discipline and restructuring actions. However, lower oil prices, foreign exchange volatility and pricing pressure remain headwinds in the near term.
Dover has a long-standing history of making successful acquisitions in diverse end-markets. In 2014, the company attained MS Printing Solutions S.r.l., The WellMark Company and Liquip International. Further in Oct 2014, Dover took over Accelerated Companies to bolster its position in the U.S. shale market. The impact of accomplished acquisitions on earnings will be of 1 cent to 3 cents per share in 2015. Further acquisitions will drive Dover’s growth.
Dover has sold two businesses during the past three years in addition to the Knowles spin-off. The company has also aggressively taken restructuring actions over the last two quarters to better align its cost base. In April 2015, Dover accomplished the sale of its Sargent Aerospace & Defense unit to RBC Bearings Inc. The divestment will assist the company reduce its exposure to cyclical markets and focus on higher margin growth spaces.
Dover Corporation manufactures and sells a range of equipment and components, specialty systems, and support services in the United States. The company operates in four segments: Energy, Engineered Systems, Fluids, and Refrigeration & Food Equipment. The Energy segment provides solutions and services for the production and processing of oil, natural gas liquids, and gas to drilling and production, bearings and compression, and automation end markets.
TE Connectivity Ltd (NYSE:TEL)‘s shares drop -0.19% to $69.02, during the current trading session Wednesday’s, hitting its highest level.
TE Connectivity Ltd. (TEL) released its fifth annual Corporate Responsibility (CR) report recently, outlining the company’s progress across a range of areas, counting its impact on the environment, the communities it serves and the workplace it creates for its employees.
Highlights from TE’s 2014 Corporate Responsibility report comprise:
- The Community:TE and the TE Connectivity Foundation supported more than 1,500 charitable organizations in 2014, contributing a total of $5.47 million to charities worldwide. Overall, volunteer hours raised from about 15,000 to 16,700 hours by TE employees in the U.S. and Mexico, in part due to TE’s “Dollars for Doers” program which donates funds to nonprofit organizations where employees volunteer their time.
- The Environment:The company demonstrated its commitment to environmental stewardship by reducing greenhouse gas (GHG) emissions by 25 percent since 2010. TE’s water usage has also reduced 23 percent during the same period. In 2014, TE established a Center of Excellence (CoE) to facilitate partnership and knowledge sharing about energy. The CoE is focused on ready-to-deploy projects that impact TE’s overall energy consumption, from efficient lighting controls to waste heat recovery.
TE Connectivity Ltd., together with its auxiliaries, designs and manufactures connectivity and sensors solutions. It operates through four segments: Transportation Solutions, Industrial Solutions, Network Solutions, and Consumer Solutions. The Transportation Solutions segment offers electronic components, counting terminals and connectors, relays, and sensors, in addition to application tooling, wire and heat shrink tubing, and other custom-engineered solutions for the automotive market, such as industrial and commercial vehicle, and hybrid and electric vehicle markets.
In an afternoon trade, Starwood Hotels & Resorts Worldwide Inc (NYSE:HOT)‘s shares plunge -0.83% to $81.56.
Starwood Hotels & Resorts Worldwide Inc. (HOT) declared a key milestone toward the planned spin-off of its vacation ownership business into a separate publicly traded company. Starwood Vacation Ownership (SVO), which will be named Vistana Signature Experiences, Inc. upon completion of the spin-off transaction, has filed an initial Form 10 Registration Statement (Form 10) with the U.S. Securities and Exchange Commission. The spin-off will be effected through a pro rata distribution of the new entity’s stock to Starwood stockholders, and is predictable to be accomplished in the fourth quarter of 2015.
Starwood Hotels & Resorts Worldwide, Inc., together with its auxiliaries, operates as a hotel and leisure company worldwide. The company owns, operates, and franchises luxury and upscale full-service hotels, resorts, residences, retreats, select-service hotels, and extended stay hotels under the St. Regis, The Luxury Collection, W, Westin, Le Méridien, Sheraton, Four Points, Aloft, and Element brand names.
PTC Therapeutics, Inc. (NASDAQ:PTCT), during its Wednesday’s current trading session 0.96% gain and closed at $48.15.
PTC Therapeutics, Inc. (PTCT) declared the appointment of Glenn D. Steele Jr., M.D., Ph.D. to the company’s Board of Directors. Dr. Steele served as President and Chief Executive Officer of Geisinger Health from March 2001 until May 2015 and is now Chairman of xG Health Solutions, a Geisinger spinoff.
Dr Steele formerly served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and vice president for medical affairs at the University of Chicago, in addition to the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School, President and Chief Executive Officer of Deaconess Professional Practice Group and chairman of the department of surgery at New England Deaconess Hospital in Boston. Dr. Steele serves on the board of directors of several public companies, counting, CEPHEID, Weis Markets Inc., and Wellcare Health Plans Inc. In addition, Dr. Steele serves on the governing body of several private organizations, counting Bucknell University, xG Health Solutions, and Geisinger Health System.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, in addition to develops spinal muscular atrophy, which is in Phase II clinical program.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
